Pay in 4 interest-free payments of $42.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Screening RhoA/ROCK inhibitors for the ability to prevent chronic rejection of mouse cardiac allografts
is a novel protein kinase D inhibitor
Ampiroxicam (<150 μM) dose-dependently decreases the proliferation of Panc-1 cells
which has results C96H120N12Na6O21
InChi: InChI=1S/C12H6ClFN4O3/c13-6-3-7(14)5-8(4-6)15-10-2-1-9-11(17-21-16-9)12(10)18(19)20/h1-5
A-836339 60106 Screening RhoA/ROCK inhibitors for theA 836339 is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB2, with Ki values of 0. 64 nM at CB2 vs 270 nM at the psychoactive CB1 receptor, but while it exhibits selective analgesic, anti inflammatory and anti hyperalgesic effects at low doses, its high efficacy at both targets results in typical cannabis like effects appearing at higher doses, despite its low binding affinity for
US$ 30.00
US$ 119.50
US$ 32.00
US$ 22.00
US$ 82.00